Novel targeted therapies hold the most promise for improving outcomes for patients with acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML). This is the conclusion published in two reports by Decision Resources. Key Opinion Leaders (KOL) and medical experts interviewed for these reports are enthusiastic about the potential of blinatumomab (Amgen/MicroMet),…

Adding a drug that activates genes to frontline combination therapy for acute myeloid leukemia (AML) resulted in an 85% remission rate after initial treatment, researchers at The University of Texas MD Anderson Cancer Center reported at the 53rd Annual Meeting of the American Society of Hematology.



"Results of the Phase II clinical trial of 75…

According to a new study by researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, older people with acute myeloid leukemia and normal looking chromosomes in their cancer cells have a higher risk of recurrence if they have mutations in a gene called ASXL1 (additional sex combs like 1).



The findings were presented at the 53rd…

Results from a multi-center Phase I study that explored multiple dosing schedules of oral azacitidine in 23 patients with acute myeloid leukemia (AML), myelodysplastic syndromes or chronic myelomonocytic leukemia (CMML) who were not candidates for other therapies or who had failed previous regimens showed a potential treatment benefit. Findings from this study were presented during the 53rd Annual Meeting of the American Society…

Research over the last several decades has helped deliver improved therapeutic options for patients suffering from leukemia, a condition that still remains lethal. New options to help diagnose the condition earlier and new therapies that will extend patients’ lives are needed. Research from a number of major studies addressing important updates on the diagnosis and treatment of leukemia were presented at the 53rd Annual Meeting of…

First, findings from preclinical studies showed that treatment with a novel oral agent, PLX3397, a selective kinase inhibitor that down-modulates macrophages, microglia, osteoclasts and mast cells, re-programmed the tumor microenvironment, supporting further development of this single agent treatment for certain cancers and malignancies such as prostate cancer. Is scientific findings was presented during the AACR-NCI- EORTC International Conference on Molecular Targets and Cancer…

Blacks and Hispanics have fewer cases of acute leukemia compared to whites but they die at a substantially higher rate, according to study results presented at the Fourth AACR Conference on The Science of Cancer Health Disparities, held in Washington DC, September 18-21, 2011.



From 1998 to 2008, blacks had a 17% increased risk of dying from acute leukemia and Hispanics had a 12% increased risk compared to white patients. When separated into the two forms of…

Worldwide more than eight million people die of cancer each year. The chance of survival depending on the type of cancer, the stage at which it is diagnosed and the speed with which appropriate treatment is launched. Skyline Diagnostics, a Dutch company associated with the Erasmus Medical Center in Rotterdam, has developed a unique diagnostic test for…

More individualized therapy and better supportive care helped push the survival for children with Acute Myeloid Leukemia (AML) to 71% three years after diagnosis, according to new research led by investigators at St. Jude Children's Research Hospital, an internationally recognized…